As of Jul 31
| +4.62 / +7.48%|
The 9 analysts offering 12-month price forecasts for Pacira Pharmaceuticals Inc have a median target of 89.00, with a high estimate of 106.00 and a low estimate of 69.00. The median estimate represents a +34.00% increase from the last price of 66.42.
The current consensus among 9 polled investment analysts is to Buy stock in Pacira Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.